文献速递泌尿男性生殖肿瘤

美国食品药品监督管理局/欧洲药品管理局批准的程序性细胞死亡配体-1检测在尿路上皮癌中的性能:以阿替利珠单抗和帕博利珠单抗一线治疗分层为重点

Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab.
PubMed 文献 · Eur J Cancer · 2018-12-05

该研究分析了251例尿路上皮癌组织芯片,比较四种FDA/EMA批准的PD-L1检测(Dako 28-8、22c3、Ventana SP263、SP142)的染色一致性及对一线阿替利珠单抗/帕博利珠单抗治疗分层的影响。结果显示Dako 28-8、22c3与SP263检测间总体百分比一致率为93.3%,而SP142与其他三种检测间仅84.1%;SP142识别出的符合一线治疗条件的患者更少。

要点

  • Dako 28-8、22c3与Ventana SP263检测间总体百分比一致率为93.3%。
  • SP142与其他三种检测间总体百分比一致率为84.1%。
  • SP142检测识别的一线阿替利珠单抗/帕博利珠单抗合格患者更少。

核心结论

  • Dako 28-8、22c3和SP263检测显示可互换的性能;SP142检测显示不同的染色结果;检测间变异性导致一线阿替利珠单抗和帕博利珠单抗合格患者的检出率不同。

研究设计与样本

  • 对251例尿路上皮癌组织芯片进行分析,每种肿瘤取四个芯;在认证实验室的Ventana Benchmark Ultra和Dako Link 48自动染色仪上染色;由两名训练有素的病理学家逐种检测判读。

主要发现

  • Dako 28-8、22c3和Ventana SP263检测间相关性高(r范围0.83-0.91);Ventana SP142与其余三种检测间相关性中等(r范围0.66-0.75)。
  • Dako 28-8、22c3和Ventana SP263检测间总体百分比一致率为93.3%。
  • 包括SP142在内的总体百分比一致率为84.1%。
  • Dako 28-8、22c3和SP263检测不同评分算法的汇总阳性百分比一致率为89.4%,汇总阴性百分比一致率为95.3%;SP142检测的汇总阳性百分比一致率为59.1%。
  • SP142检测识别的一线阿替利珠单抗/帕博利珠单抗治疗合格患者更少。

关键数值与推荐

  • Dako 28-8、22c3和Ventana SP263检测间相关性高(r范围0.83-0.91)。
  • Ventana SP142与其余三种检测间相关性中等(r范围0.66-0.75)。
  • Dako 28-8、22c3和Ventana SP263检测间总体百分比一致率为93.3%。
  • 包括SP142在内的总体百分比一致率为84.1%。
  • Dako 28-8、22c3和SP263检测不同评分算法的汇总阳性百分比一致率为89.4%,汇总阴性百分比一致率为95.3%;SP142检测的汇总阳性百分比一致率为59.1%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recently, the Food and Drug Administration (FDA)/European Medicines Agency (EMA) restricted first-line use of atezolizumab and pembrolizumab in patients with metastasised urothelial carcinoma by defining distinct programmed cell death ligand-1 cut-offs. We analysed the diagnostic performance of all FDA/EMA-approved programmed cell death ligand-1 assays with emphasis on new restrictions for first-line treatment with atezolizumab and pembrolizumab. PATIENTS AND METHODS: Two hundred fifty-one urothelial carcinomas were analysed on tissue microarrays with four cores of each tumour. Stains were performed in certified laboratories on Ventana Benchmark Ultra and Dako Link 48 autostainers. Stains were read on an assay-by-assay basis by two trained pathologists. Overall percentage agreement (OPA) was calculated across the preset cut-offs. Positive percentage agreement (PPA) and negative percentage agreement (NPA) were calculated across different scoring algorithms. Venn diagrams were constructed to illustrate discordance according to the recent FDA/EMA guidelines. RESULTS: The Dako 28-8, 22c3 and the Ventana SP263 assays showed high interassay correlation (r-range 0.83-0.91). Interassay correlation between the Ventana SP142 and the three other assays was moderate (r-range 0.66-0.75). OPA of 93.3% was achieved between the Dako 28-8, 22c3 and Ventana SP263 assays. OPA including the SP142 was 84.1%. Pooled PPA and NPA of different scoring algorithms was 89.4% and 95.3% for the Dako 28-8, 22c3 and the SP263 assays, respectively. With the SP142 assay, pooled PPA was 59.1%. The SP142 assay identifies fewer eligible patients for first-line treatment with atezolizumab/pembrolizumab. CONCLUSION: Dako 28-8, 22c3 and SP263 assays show interchangeable performance. The SP142 assay shows divergent staining results. Interassay variability leads to different detection rates of eligible patients for first-line treatment with atezolizumab and pembrolizumab.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Eckstein M, Erben P, Kriegmair MC, et al. Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab. Eur J Cancer. 2018. PMID: 30528808. doi:10.1016/j.ejca.2018.11.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。